Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
C9 single-chain variable fragment
- Development stage
- Preclinical
- Lead developer
- Var2 Pharmaceuticals
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
C9 single-chain variable fragment is a recombinant, human-derived antibody fragment developed by Var2 Pharmaceuticals that specifically targets oncofetal chondroitin sulfate (ofCS). ofCS is a unique glycosaminoglycan modification that is essentially absent from healthy adult tissues but is highly expressed on the surface of a wide variety of cancer cells and in the placenta. The C9 scFv was discovered through phage display screening to identify binders that mimic the high-affinity interaction between the malaria protein VAR2CSA and ofCS. This scFv is utilized as a modular targeting domain in the development of next-generation cancer therapies, including Chimeric Antigen Receptor (CAR) T-cells and bispecific antibodies, aimed at treating a broad spectrum of solid tumors such as colorectal, pancreatic, and lung carcinomas.
- Other names
- anti-ofCS scFv C9C9 single-chain antibody fragmentC-9 single-chain antibody fragmentC 9 single-chain antibody fragment
02
Targets
ofCS (Oncofetal chondroitin sulfate)
Beyond the preview
Go deeper on C9 single-chain variable fragment.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on C9 single-chain variable fragment.